60 results
10-K
2014 FY
LRMR
Larimar Therapeutics Inc
25 Mar 15
Annual report
12:00am
in patients with PWS in the European Union in the middle of 2015. Beloranib received orphan designation for the treatment of PWS by both the U.S. Food … States and in the European Union ranges from 1 in 8,000 to 1 in 50,000. The physiological drive to eat in patients with PWS is so powerful
424B4
LRMR
Larimar Therapeutics Inc
23 Jan 15
Prospectus supplement with pricing info
12:00am
of beloranib in patients with PWS in the European Union in the middle of 2015, with 12-month data anticipated in late 2016. Beloranib received orphan … of a patient with PWS.
Published population studies estimate that the prevalence of PWS in the United States and in the European Union ranges from 1
424B4
0btcnh fziu1d
19 Jun 14
Prospectus supplement with pricing info
12:00am
8-K/A
EX-99.2
3547 wolt
26 Jun 20
Other Events
5:08pm
S-1
zm6p7dp
18 Apr 14
IPO registration
12:00am
8-K
EX-99.1
8ogut5mz3r
2 Jun 20
Chondrial Therapeutics and Zafgen Complete Merger and Begin Operating as Larimar Therapeutics
7:49am
8-K
EX-99.1
agry pbww5
12 Jan 15
Other Events
12:00am
8-K
EX-99.1
ms02aci3kmxs40gay
11 Aug 20
Larimar Therapeutics Reports Second Quarter 2020 Operating and Financial Results
7:38am